| Field | Specification |
|---|---|
| Target | |
| Alternative names | Zinc finger protein Aiolos; Ikaros family zinc finger protein 3; IKZF3; ZNFN1A3 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derivedhumanIKZF3recombinantprotein(Position:M1-H456).HumanIKZF3?shares?85.5%?amino?acid?(aa)?sequence?identity?withmouseIKZF3. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes zinc finger protein Aiolos (gene IKZF3) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 58.0 kDa, and the supplier reports an observed band at about 70 kDa.
Aiolos (IKZF3) is a zinc finger transcription factor of the Ikaros family expressed mainly in lymphocytes. It regulates B-cell differentiation and maturation and influences T-cell survival through BCL2, and it is a known target of degradation by the immunomodulatory drugs lenalidomide and pomalidomide.
| Target | Zinc finger protein Aiolos (gene IKZF3; UniProt Q9UKT9, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 58.0 kDa |
| Observed MW | 70 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human Raji cells, human Ramos cells, mouse thymus tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human tonsil tissue, rat thymus tissue, mouse spleen tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): SIHA cells.
Samples with a confirmed signal (flow cytometry): THP-1 cells.
Immunogen
E. coli-derivedhumanIKZF3recombinantprotein(Position:M1-H456).HumanIKZF3?shares?85.5%?amino?acid?(aa)?sequence?identity?withmouseIKZF3.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places zinc finger protein Aiolos in the nucleus, cytoplasm and SUBCELLULAR LOCATION:. Tissue expression noted by UniProt (human): Expressed most strongly in peripheral blood leukocytes, the spleen, and the thymus. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
